Immunotherapy for Alzheimer’s disease: hoops and hurdles

Molecular Neurodegeneration

Cynthia A Lemere¹ 

[1] Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, NRB 636F, 77 Avenue Louis Pasteur, Boston 02115, MA, USA

关键词: BACE-1;    Tau;    Pyroglutamate Aβ;    Amyloid-β;    Vaccine;    Immunotherapy;   

Others  :  862093
DOI  :  10.1186/1750-1326-8-36

 received in 2013-07-03, accepted in 2013-09-23,  发布年份 2013

【 摘 要 】

Alzheimer’s disease (AD) is the most common form of dementia, afflicting more than 30 million people worldwide. Currently, there is no cure or way to prevent this devastating disease. Extracellular plaques, containing various forms of amyloid-β protein (Aβ), and intracellular neurofibrillary tangles (NFTs), composed of hyper-phosphorylated tau protein, are two major pathological hallmarks of the AD brain. Aggregation, deposition, and N-terminal modification of Aβ protein and tau phosphorylation and aggregation are thought to precede the onset of cognitive decline, which is better correlated with tangle formation and neuron loss. Active and passive vaccines against various forms of Aβ have shown promise in pre-clinical animal models. However, translating these results safely and effectively into humans has been challenging. Recent clinical trials showed little or no cognitive efficacy, possibly due to the fact that the aforementioned neurodegenerative processes most likely pre-existed in the patients well before the start of immunotherapy. Efforts are now underway to treat individuals at risk for AD prior to or in the earliest stages of cognitive decline with the hope of preventing or delaying the onset of the disease. In addition, efforts to immunize against tau and other AD-related targets are underway.

【 授权许可】

   
2013 Lemere; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Alzheimer’s Association: 2013 Alzheimer’s disease facts and figures. Alzheimers Dement 2013, 9(2):1-71.
• [2]Perrin RJ, Fagan AM, Holtzman DM: Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature 2009, 461:916-922.
• [3]Selkoe DJ: Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
• [4]Lemere CA, Masliah E: Can Alzheimer’s disease be prevented by amyloid β immunotherapy? Nat Rev Neurol 2010, 6:108-119.
• [5]Solomon B, Koppel R, Hanan E, Katzav T: Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci U S A 1996, 93:452-455.
• [6]Solomon B, Koppel R, Frenkel D, Hanan-Aharon E: Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997, 94:4109-4112.
• [7]Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
• [8]Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Boada Rovira M, Forette F, Orgogozo J-M: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
• [9]Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JAR: Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
• [10]Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, Nicoll JAR: Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease. Acta Neuropathol 2010, 120:13-20.
• [11]Ryan JM, Grundman M: Anti-amyloid-beta immunotherapy in Alzheimer’s disease: ACC-001 clinical trials are ongoing. J Alzheimer Dis 2009, 17:243.
• [12]Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennw K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A: Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012, 11:597-604.
• [13]Schneeberger A, Mandler M, Otava O, Zauner W, Mattner F, Schmidt W: Development of Affitope vaccines for Alzheimer’s disease (AD) – from concept to clinical testing. J Nutr Health Aging 2009, 13:264-267.
• [14]Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens N, Meerschman C, van der Auwera I, Van Leuven F, Sugawara M, Weingertner M-C, Bechinger B, Greferath R, Kolonko N, Nagel-Steger L, Riesner D, Brady RO, Pfeifer A, Nicolau C: Liposomal vaccines with conformation-specific amyloid antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci USA 2007, 104:9810-9815.
• [15]Bard F, Cannon C, Barbour R, Burke R-L, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T: Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.
• [16]Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello KA, Rodriguez Martinez de Llano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M: 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010, 9:363-372.
• [17]Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M: Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298:1379.
• [18]Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D: Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004, 1:24. BioMed Central Full Text
• [19]Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB: Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005, 25:629-636.
• [20]Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Grundman M: Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012, 11:241-249.
• [21]DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-a beta antibody alters CNS and plasma a beta clearance and decreases brain a beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 2001, 98:8850-8855.
• [22]Dodart J-C, Bales K, Gannon K, Greene S, DeMattos R, Mathis C, DeLong C, Wu S, Wu X, Holtzman D, Paul S: Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer’s disease model. Nature Neurosci 2002, 5:452-457.
• [23]Farlow M, Arnold SE, Van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER: Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement 2012, 8:261-271.
• [24]Lilly Press Release 2012. https://investor.lilly.com/releasedetail.cfm?releaseid=711933 webcite
• [25]Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango-L JC, Anthony DC, Koo E, Goate A, Selkoe DJ, Arango-V JC: The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nat Med 1996, 2:1146-1150.
• [26]Lopera F, Ardilla A, Martinez A, Madrigal L, Arango-Viana JC, Lemere CA, Arango-Lasprilla JC, Hincapie L, Arcos-Burgos M, Ossa JE, Behrens IM, Norton J, Lendon C, Goate AM, Ruiz-Linares A, Rosselli M, Kosik KS: Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997, 277:793-799.
• [27]Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ: An effector-reduced anti-Aβ-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 2012, 32:9677-9689.
• [28]Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H: Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis 2012, 28:49-69.
• [29]Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S: Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995, 14:457-466.
• [30]Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, Demuth HU: On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 2006, 45:12393-12399.
• [31]Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth H-U, Lemere CA: Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer’s-like transgenic mice: a pilot study. Neurodegenerative Dis 2012, 10:265-270.
• [32]Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawar S, Kuma S, Multhaup G, Walter J, Ingelsson M, Degerman-Gunnarsson M, Kalimo H, Huitinga I, Lannfelt L, Bayer TA: Identification of low molecular weight pyroglutamate Aβ oligomers in Alzheimer disease. J Biol Chem 2010, 285:41517-41724.
• [33]DeMattos RB, Lu J, Tang Y, Racke MM, DeLong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML: A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer’s disease mice. Neuron 2012, 76:908-920.
• [34]Loeffler DA: Intraveneous immunoglobulin and Alzheimer’s disease: what now? J Neuroinflammation 2013, 10:70. doi:10.1186/1742-2094-10-70 BioMed Central Full Text
• [35]Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F: Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013, 12:233-243.
• [36]Alzforum News: GammagardTM misses endpoints in phase 3 trial. http://www.alzforum.org/new/detail.asp?id=3485 webcite
• [37]Rosemann H: Immunotherapy for targeting tau pathology in Alzheimer’s disease and tauopathies. Curr Alzheimer Res 2013, 10:217-228.
• [38]Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, Lemere CA: MER5101, a Novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1dE9 transgenic mice. J Neurosci 2013, 33:7027-7037.